
FDA Approves Venglustat, First Treatment for Neurological Symptoms of GD3
Key Takeaways
- FDA authorized venglustat for GD3 neurologic symptoms in patients ≥15 kg, marking the first CNS-directed option in a setting where ERT and prior SRTs failed to deliver neurologic benefit.
- LEAP2MONO randomized 43 ERT-stabilized patients (≥12 years) to once-daily venglustat versus biweekly IV ERT for 52 weeks using a double-blind, double-dummy, active-comparator design.
The oral glucosylceramide synthase inhibitor crosses the blood-brain barrier, addressing a neurological component of the disease that enzyme replacement therapy cannot reach.
The FDA approved venglustat (Infilbray; Sanofi) tablets as the first treatment for the neurological symptoms of type 3 Gaucher disease (GD3) in adults and pediatric patients who weigh at least 15 kg (about 33 lb), according to an FDA news release issued November 18, 2026. The approval was supported by data from the phase 3 LEAP2MONO clinical trial (NCT05222906).1,2
GD3 is a rare, inherited lysosomal storage disorder in which a deficient or malfunctioning glucocerebrosidase enzyme prevents the body from properly breaking down glucosphingolipids, which then accumulate in organs, tissues, and the brain.1,3 Unlike type 1 Gaucher disease, which typically lacks central nervous system involvement, GD3 is a chronic neuronopathic form that affects balance, coordination, speech, memory, and thinking, and these symptoms can worsen over time.1,3 Patients also experience systemic manifestations, including hepatosplenomegaly, anemia, thrombocytopenia, and bone disease.3,4
Until now, available therapies have addressed only the systemic features of GD3. ERT does not cross the blood-brain barrier and has not demonstrated cognitive or oculomotor benefit, and existing oral substrate reduction therapies have either been excluded from the brain (eliglustat) or proved ineffective for neurological symptoms (miglustat).4
Venglustat is an oral glucosylceramide synthase inhibitor designed to cross the blood-brain barrier, reducing the buildup of glycosphingolipids throughout the body and within the brain.1,3
“For patients with GD3, harmful substances build up in the brain without a way to stop them, but this drug's ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms,” Kyle Diamantas, JD, acting FDA Commissioner, said in the news release. “This approval reflects the FDA’s commitment to advancing therapeutic options for patients with rare diseases and brings an important new treatment to patients and the healthcare providers who care for them.”1
Findings from the LEAP2MONO Clinical Trial
The approval was based on results from the randomized, double-blind, double-dummy, active-comparator phase 3 LEAP2MONO trial (NCT05222906).1,2 The study enrolled 43 patients aged 12 years and older with GD3 who had received ERT for at least 3 years and achieved therapeutic goals for systemic disease.1-3 Patients were randomly assigned 1:1 to once-daily oral venglustat (n = 21) or intravenous enzyme replacement therapy (ERT) every 2 weeks (n = 22) for a 52-week duration.3
The primary end points were change from baseline to week 52 in the Scale for the Assessment and Rating of Ataxia (SARA) modified total score and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score, which the FDA evaluated as a single combined measure of neurological symptoms. At week 52, patients who were treated with venglustat demonstrated a statistically significant improvement on this measure compared with those receiving ERT.1-3
Venglustat also performed comparably with ERT on key systemic secondary end points, including spleen volume, liver volume, and hemoglobin levels, meeting 3 of 4 key secondary end points.3
"A daily pill could make a serious difference for [patients with GD3] facing neurological challenges," said Houman Ashrafian, executive vice president and head of research and development at Sanofi, when the topline results were announced in February.3
Earlier Evidence
The phase 3 results build on the phase 2 LEAP trial (NCT02843035)5, an open-label study of 11 adults with GD3 who received venglustat 15 mg once daily in addition to maintenance imiglucerase.4,5 Venglustat crossed the blood-brain barrier and, after 1 year, reduced median cerebrospinal fluid glucosylceramide and glucosylsphingosine levels by 81% and 70%, respectively.4 Additionally, modified SARA scores improved modestly (mean change, −1.14; 95% CI, −2.06 to −0.21), with 9 of 11 patients improving. The investigators noted that the uncontrolled design required confirmation of these findings in controlled studies.4
Safety
The most frequently reported adverse effects (AEs) with venglustat were gastrointestinal symptoms and mood-related effects.1 In LEAP2MONO, the most common AEs among patients receiving venglustat vs ERT were headache (14.3% vs 18.2%), nausea (14.3% vs 4.5%), splenomegaly (14.3% vs 0%), and diarrhea (14.3% vs 0%).3
Serious psychiatric risks, including suicidal ideation and behavior, have been reported. Further, studies evaluating animal models also identified potential lens opacities (eg, clouding of the lens of the eye) in younger patients and AEs on fetal development when the drug is administered during pregnancy.1
Implications for Pharmacists
As the first oral therapy to target the neurological manifestations of GD3, venglustat may change how patients and caregivers approach long-term disease management. Pharmacists can play a role in counseling patients and families to monitor for mood changes or suicidal thoughts, reviewing pregnancy status and contraception needs, and coordinating care with specialists, particularly for pediatric patients, given the animal data on lens effects. It is recommended that pharmacists should consult the full prescribing information for dosing, monitoring, and drug interaction guidance.
Venglustat received orphan drug and priority review designations from the FDA1, as well as fast track designation for GD3.3 The approval follows the January 2026 expansion of the imiglucerase (Cerezyme; Sanofi) label to include non–central nervous system manifestations of GD3.3
REFERENCES
FDA approves first drug to treat neurological symptoms of type 3 Gaucher disease. News release. FDA. November 18, 2026. Accessed November 18, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease
A study to evaluate the efficacy and safety of venglustat compared with enzyme replacement therapy in participants with type 3 Gaucher disease (LEAP2MONO). ClinicalTrials.gov identifier: NCT05222906. Updated July 13, 2026. Accessed November 18, 2026. https://clinicaltrials.gov/study/NCT05222906
Venglustat met all primary endpoints in phase 3 study in type 3 Gaucher disease. News release. Sanofi. February 2, 2026. Accessed November 18, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-02-06-00-00-3229947
Schiffmann R, Cox TM, Dedieu JF, et al. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial. Brain. 2023;146(2):461-474. doi:10.1093/brain/awac379
Venglustat combined with imiglucerase in adults with type 3 Gaucher disease (LEAP). ClinicalTrials.gov identifier: NCT02843035. Updated July 10, 2026. Accessed November 18, 2026. https://clinicaltrials.gov/study/NCT02843035
Related to this article








